LED Medical Diagnostics Inc. (TSX VENTURE:LMD) announced today that

its VELscope Vx enhanced early detection system has just been approved

for use by AppleWhite Dental Partners. The VELscope Vx is exclusively

distributed in the U.S. and Canada by Henry Schein, Inc.


"We are very pleased that the VELscope Vx has received the approval of

yet another demanding and respected group dental practice," said Peter

Whitehead, founder and CEO of LED Dental and its parent company, LED

Medical Diagnostics Inc. (TSX VENTURE:LMD). "AppleWhite Dental

Partners takes great pains to select only the finest technologies for

its practices and their patients, and it is very gratifying to have

them approve our VELscope Vx."

LED Dental introduced the first generation of VELscope's fluorescence

visualization technology about five years ago in response to the fact

that oral cancer was one of the few types of cancer that had not

experienced a significant decline in mortality over the previous

several decades. VELscope technology gives dental practitioners an

adjunctive visualization aid that should be used together with, and

after, a traditional intra-and extra-oral head and neck exam in hopes

of detecting oral lesions that might otherwise have been overlooked.

"Our mission is to create a partnership with our dentists that allow

them to practice innovative dentistry and provide an outstanding

patient experience," said Dr. Thomas McCoy, CEO of AppleWhite Dental

Partners. "Adding the state-of-the-art VELscope Vx enhances the

ability of our dentists to discover oral cancer and other oral disease

in early stages, and in a way that is completely non-invasive for

their patients."

The National Cancer Institute's SEER website indicates that oral

cancer is most often detected in late stages, when the 5-year survival

rate is less than 50%. When detected early, however, the 5-year

survival rate leaps to approximately 82%. Because the VELscope Vx is

so sensitive to oral mucosal changes, it can help increase the odds

that cancer will be detected in early and even precancerous stages.

"In fact," said Mr. Whitehead, "VELscope technology increases the

likelihood of detecting all types of oral disease at earlier stages,

which is good news for the patient as well as the practice."

Since the launch of the first generation model, over 10,000 VELscope

devices have been purchased by dental practices globally. It is

estimated that these devices have been used to conduct over 10 million

oral cancer exams during that time, easily making the VELscope the

world's number one adjunctive oral cancer screening technology.

The VELscope Vx, the latest generation of the technology, is the first

to offer cordless convenience as well as an optional digital camera

and customized bracket that make it easy for dentists to

photo-document suspicious lesions that are referred to specialists for

surgical biopsy.

"We have considered all available options," said Dr. Mark Mosier,

Director of Dentistry for AppleWhite Dental Partners, "and we are

confident that the VELscope Vx offers the most effective, most

convenient and most economical solution for both our practices and

their patients."

AppleWhite Dental Partners provides an array of services to 17

participating dental practices in Iowa, Illinois and Minnesota. By

providing business support, professional mentoring, and administrative

and consulting services, AppleWhite Dental Partners allows its

participating dentists to devote their time to caring for patients,

continuing education, and honing clinical skill.

About LED Medical Diagnostics Inc.

Founded in 2003, LED Medical Diagnostics Inc., (TSX VENTURE:LMD) is a

fast-growing public company offering effective early-stage oral cancer

detection technologies in 23 countries worldwide. The company makes

the VELscope Vx, a powerful tool for detecting early stage oral cancer

that is approved by the FDA, Health Canada and European regulators.

The company is headquartered in Burnaby British Columbia, Canada. For

more information please call +1 (604) 434-4614, or visit

About the VELscope Vx

The VELscope Vx is a powerful FDA-approved tool used to screen for

oral cancer. It saves lives by helping detect early stage oral cancer

and pre-cancer and other abnormalities in the mouth such as viral,

fungal and bacterial infections. The VELscope Vx is exclusively

distributed worldwide through a partnership with Henry Schein, the

world's largest dental distribution company. For more information

please call +1 (604) 434-4614, or visit